EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

October 11, 2022

Filipa Ferreira

EU Cosmetics Regulation (EC) No 1223/2009 and Fragrance Allergens

Fragrance substances are organic compounds with characteristic, usually pleasant, odours. These substances are widely used in perfumes and perfumed cosmetic products, but also in detergents, fabric softeners and other household products. Fragrance substances are commonly linked to contact allergies. These allergies are life-long altered specific reactivities in the human immune system. Contact allergy comprehends two phases: induction and elicitation phase. The induction phase, also called sensitization, comprehends the activation of the immune system, and during this phase, no clinical symptoms are developed. Re-exposure to a sufficient amount of the substance, or a cross-reacting allergen can provoke the initiation of the elicitation phase and cause clinically visible allergic symptoms like eczema (allergic contact dermatitis). Restriction limits can be deemed sufficient to prevent allergic reactions. However, people that are already sensitized may develop symptoms when exposed to lower concentrations of an allergen than the maximum permitted levels.

According to Article 19 of the Regulation (EC) No 1223/2009, a cosmetic product is to be made available on the European Union market only where a list of ingredients is indicated on its labelling. Currently, 25 fragrance allergens are listed in Annex III, entries 67 to 92, which means that these allergens must be indicated in the label of the cosmetic product when their concentration exceeds 0.001% in leave-on or 0.01% in rinse-off products.

Notification to the World Trade Organizations (WTO)

In response to the request of the European Commission for an update of the list of individually labelled fragrance allergens, the Scientific Committee on Consumer Safety (SCCS) published an opinion in 2012, identifying 56 additional fragrance allergens, which have clearly caused allergies in humans. Additionally, fragrance substances such as prehaptens and prohaptens, that can be transformed to known contact allergens via air oxidation or bioactivation, should be treated as equivalent to fragrance allergens and be subject to the same restrictions and other regulatory requirements.

On 15 September 2022, the World Trade Organization (WTO) was notified by the European Commission about new amendments to the European Cosmetic Regulation, regarding the labelling of fragrance allergens in cosmetic products. According to the notification, an obligation to individually label those fragrance allergens will be introduced in Annex III (list of substances which cosmetic products must not contain except subject to the restrictions laid down) to Regulation (EC) No 1223/2009, with the same restrictions followed by already listed allergens. This change takes the total number of allergens to be considered and potentially labelled to 81. Examples of the allergens expected to be included in Annex III are: Benzaldehyde (CAS number: 100-52-7), Camphor (CAS number: 76-22-2/ 21368-68 -3/ 464-49-3/ 464- 48-2) and Menthol (CAS number: 89-78-1/ 1490-04-6/ 2216 -51-5). Certain entries of Annex III are also expected to be updated.

Regarding these new restrictions, there should be a reasonable period of adaptation for the economic operators to make the necessary adjustments to the cosmetic products and containers, as well as to withdraw from the market non-compliant cosmetic products.

The proposed date of adoption of the new labelling requirements is expected to be in the first half of 2023. The draft regulation include a transition period of 3 years for products being placed on the market and 5 years for the withdrawal of non-compliant products.

The draft regulation is open for comment until November 14, 2022.

What is expected in the UK?

As of today, there are no plans for the UK government to implement this new requirement for cosmetic products placed on the market of Great Britain (England, Scotland, and Wales). However, as Northern Ireland still follows EU rules, this new labelling will be required for products sold there.

Reach out to our team for further information at info@criticalcatalyst.com.

References:

SCCS opinion on fragrance allergens in cosmetic products (2012);
European Commission, Final report: Impact assessment study on fragrance labelling on cosmetic products (2020);
Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products;
Committee on Technical Barriers to Trade – Notification – European Union – Fragrance allergens in cosmetic products. G/TBT/N/EU/924. 15 September 2022.

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Guilherme Semedo February 24, 2023

medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Guilherme Semedo February 15, 2023

medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Guilherme Semedo February 13, 2023

medical devices

Reclassification of Active Products without Intended Medical Purpose in the European Union

The Commission published the Implementing Regulation (EU) 2022/2347, laying down rules for the reclassification of several active products without an intended medical purpose mentioned in MDR annex XVI.

Guilherme Semedo January 24, 2023

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Guilherme Semedo January 9, 2023

medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Guilherme Semedo December 13, 2022

medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Liliana Teles December 10, 2022

cosmetic products

Regulation (EU) 2022/2195 – Updates to cosmetic ingredients use requirements

Ingredients: BHT, ACID YELLOW 3, HOMOSALATE, HAA299 and RESORCINOL

Date of publication: 11/11/2022

Date of application: 01/07/2023

Commission Regulation (EU) 2022/2195 of November 2022 amends Regulation (EC) No 1223/2009, restricting the use of BHT, Acid Yellow 3, Homosalate, HAA299 and Resorcinol, in cosmetic products.

Liliana Teles November 11, 2022

medical devices

Availability of Medical Devices in Europe After MDR Implementation – Findings From Medtech Europe Survey Report

Implementation of the MDR is a top priority for the medical devices industry, which has committed significant resources to comply with the new requirements. Despite its efforts, the sector remains seriously held back by the slow and piecemeal implementation of the new regulatory framework.

Liliana Teles October 13, 2022

cosmetic products